Sign in

Hospital-Acquired Infection Diagnostics Market Trends, Technological Advancements, Company Profile and Growth Opportunities

Pramod Kumar
Hospital-Acquired Infection Diagnostics Market Trends, Technological Advancements, Company Profile and Growth Opportunities

The HAI diagnostics market size is projected to cross $4.3 billion by 2023, growing at a CAGR of 7.6% between 2017-2023.

In terms of application, the HAI diagnostics market is segmented into drug-resistance testing and disease testing. The drug-resistance testing held the larger share in the market in 2016, owing to the modernization in molecular diagnostics that has enabled drug-resistance testing. With the development of novel testing techniques such as phenotypic resistance testing, hybridization methods, sample processing and sequencing the diagnosis rate has increased to may folds and is expected to grow in near future.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hospital-acquired-infection-diagnostics-market/report-sample

The European HAI diagnostics market is projected to grow at a steady pace during 2017-2023, to cross $1.2 billion by 2023. According to the International Trade Administration (ITA), there is growth in the market, with the major companies such as Roche Diagnostics Limited, Abbott Laboratories, and others investing more in the R&D of the innovative diagnostics products to remain competitive in this field. Along with it, the growth of the hospital acquired diagnostics market in Europe is also characterized by the increase in geriatric population and high incidence of hospital acquired infections.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hospital-acquired-infection-diagnostics-market

Technologically advanced products aid by offering accurate and reliable results with low turnaround time. Major companies in the HAI diagnostics market are investing in the development of the molecular diagnostics, looking forward to the growth and demand in the field. For instance, Roche diagnostics, in 2017, launched cobas Liat PCR system with four assays, which also include 20-minute real-time PCR nucleic acid test to detect Clostridium difficile. The company also launched cobas HPV for using on cobas 6800/8800 system for cervical cancer screening, 2017. Cobas 6800/8800 system is a two integrated and fully automated molecular testing system for blood and plasma donor screening. Qiagen N.V., in 2017, launched ipsogen JAK2 RGQ PCR Kit for detection of blood cancer, ipsogen portfolios common, and rare leukemia types.

Some of the key players operating in the HAI diagnostics market are Abbott Laboratories, AstraZeneca plc, Bayer AG, Daiichi Sankyo Co. Ltd., Danaher Corporation, Hologic Inc., Johnson & Johnson, OpGen Inc., and F. Hoffmann-La Roche AG.


P&S Intelligence

347, 5th Ave. #1402

New York City, NY - 10016                                

Toll-free: +1-888-778-7886 (USA/Canada)              

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook


Pramod Kumar
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more